BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma

BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying-Ying, Wu, Chunjing, Chen, Shu-Mei, Shah, Sumedh S., Wangpaichitr, Medhi, Feun, Lynn G., Kuo, Macus T., Suarez, Miguel, Prince, Jeffrey, Savaraj, Niramol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951241/
https://www.ncbi.nlm.nih.gov/pubmed/26771234
http://dx.doi.org/10.18632/oncotarget.6882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951241/
https://www.ncbi.nlm.nih.gov/pubmed/26771234
http://dx.doi.org/10.18632/oncotarget.6882

Ejemplares similares